A Study of ARRY-438162 in Patients With Rheumatoid Arthritis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00650767|
Recruitment Status : Completed
First Posted : April 2, 2008
Results First Posted : November 7, 2016
Last Update Posted : November 7, 2016
|Study Design||Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor); Primary Purpose: Treatment|
Drug: ARRY-438162, MEK inhibitor; oral
Drug: Placebo; oral
The ARRAY-162-201 study began recruitment on 04-April-2008 (First Patient First Visit) and concluded on 07-July-2009 (Last Patient Last Visit).
This study was conducted at 36 sites in the United States, Europe and South America.
|Pre-assignment Details||Participant Flow and Baseline Demographics represent the Intent-to-Treat (ITT) population, which is all patients who were randomized to a treatment group.|